SEL 110

Drug Profile

SEL 110

Alternative Names: SEL-110; SVP Rapamycin; SVP-R

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selecta Biosciences
  • Developer National Cancer Institute (USA); Selecta Biosciences
  • Class Anti-infectives; Antifungals; Antineoplastics; Gene therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mesothelioma
  • Clinical Phase Unknown Immunological disorders
  • Preclinical Methylmalonic acidaemia
  • Research Inborn urea cycle disorders

Most Recent Events

  • 21 Feb 2018 Phase-I clinical trials in Mesothelioma (Combination therapy, Second-line therapy or greater, Late-stage disease, In adults, In the elderly) in USA (Parenteral) (NCT03436732)
  • 15 May 2017 Preclinical trials in Methylmalonic acidaemia in USA prior to May 2017 (Parenteral)
  • 15 May 2017 Pharmacodynamic results from a preclinical trial in Methylmalonic acidaemia released by Selecta Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top